Dendritic cell-based immunotherapy in ovarian cancer

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-3

  Coosemans, An ^a   Vergote, Ignace ^a   Van Gool, Stefaan W ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

DC; DC immunotherapy; Dendritic cell; Ovarian cancer; WT1

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MESSENGER RNA; METRONOMIC CYCLOPHOSPHAMIDE; MUCIN 1; PROTEIN P53; RECOMBINANT EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT INTERLEUKIN 12; RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL FUSION; CELL LYSATE; DENDRITIC CELL; GLIOBLASTOMA; HIGH GRADE GLIOBLASTOMA; HUMAN; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; TUMOR GENE; WILMS TUMOR GENE 1;

EID: 84896732078     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27059     Document Type: Article

References (10)

1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al.; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943-53; PMID:20818904; http://dx.doi. org/10.1056/NEJMoa0908806
2. Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, Heitz J, Kurzeder C, du Bois A. Bevacizumab in the treatment of ovarian cancer. Adv Ther 2012; 29:723-35; PMID:22941523; http:// dx.doi.org/10.1007/s12325-012-0041-9
3. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http:// dx.doi.org/10.1158/1078-0432.CCR-09-0737
4. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:17476349; http://dx.doi. org/10.1172/JCI31205
5. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005; 12:772-82; PMID:15750615; http://dx.doi. org/10.1038/sj.gt.3302471
6. De Keersmaecker B, Heirman C, Allard S, Bonehill A, Corthals J, Thielemans K, Aerts JL. Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. Hum Gene Ther 2010; 21:479-85; PMID:19903083; http://dx.doi.org/10.1089/ hum.2009.080
7. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012; 61:2033-44; PMID:22527250; http://dx.doi.org/10.1007/ s00262-012-1261-1
8. Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res 2013; 33:3855-9; PMID:24023319
9. Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in endstage endometrial carcinoma. Anticancer Res 2010; 30:3709-14; PMID:20944158
10. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/ nrd3626